Tìm kiếm thay thế:
harm » arm (Mở rộng tìm kiếm), farm (Mở rộng tìm kiếm), hard (Mở rộng tìm kiếm)
evolved. » resolved. (Mở rộng tìm kiếm)
resolvessdsssds. » resolvedsdsssds. (Mở rộng tìm kiếm), resolvesdsssds. (Mở rộng tìm kiếm), evolvessdsssds. (Mở rộng tìm kiếm)
resolves. » resolved. (Mở rộng tìm kiếm), resolve. (Mở rộng tìm kiếm), evolves. (Mở rộng tìm kiếm)
Đang hiển thị 141 - 160 kết quả của 2,052 cho tìm kiếm 'harm is (((((resolvessdsssds. OR involves.) OR involves.) OR evolved.) OR involved.) OR resolves.)', thời gian truy vấn: 0.47s Tinh chỉnh kết quả
  1. 141
    MIS barriers and corresponding mission governance actions to which actors in the mission arena are committed.

    MIS barriers and corresponding mission governance actions to which actors in the mission arena are committed. Bằng Joeri Wesseling (16819641)

    Được phát hành 2023
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  2. 142
    Overview of strength and weaknesses of the MIS approach.

    Overview of strength and weaknesses of the MIS approach. Bằng Joeri Wesseling (16819641)

    Được phát hành 2023
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  3. 143
    Overview of interviewees.

    Overview of interviewees. Bằng Joeri Wesseling (16819641)

    Được phát hành 2023
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  4. 144
    Primers of this study.

    Primers of this study. Bằng Shuang Li (146392)

    Được phát hành 2022
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  5. 145
    Agarose gel electrophoresis results of PCR products.

    Agarose gel electrophoresis results of PCR products. Bằng Shuang Li (146392)

    Được phát hành 2022
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  6. 146
    The degradation of PNP by <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crc</i>Y, and DLL-Δ<i>crcZ</i>.

    The degradation of PNP by <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crc</i>Y, and DLL-Δ<i>crcZ</i>. Bằng Shuang Li (146392)

    Được phát hành 2022
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  7. 147
    The growth of <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crcY</i>, and DLL-Δ<i>crcZ</i> on LB medium.

    The growth of <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crcY</i>, and DLL-Δ<i>crcZ</i> on LB medium. Bằng Shuang Li (146392)

    Được phát hành 2022
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  8. 148
    Spatial distribution of overall non-carcinogenic risk (HI) for (a) infants, (b) Children, (c) adult females, and (d) adult males posed by potential harmful substances of groundwater within the Tongde Basin.

    Spatial distribution of overall non-carcinogenic risk (HI) for (a) infants, (b) Children, (c) adult females, and (d) adult males posed by potential harmful substances of groundwate... Bằng Shanhu Xiao (22226759)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  9. 149
    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings.

    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  10. 150
    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis.

    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  11. 151
    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis.

    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  12. 152
    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference.

    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  13. 153
    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis.

    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  14. 154
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  15. 155
    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis.

    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  16. 156
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  17. 157
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  18. 158
    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  19. 159
    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:
  20. 160
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... Bằng Diana M. Hendrickx (1507435)

    Được phát hành 2025
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: